Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off

Core Insights - Vir Biotechnology has significantly transformed its strategic focus and technological platforms since July, phasing out its vaccines and viral immunotherapy programs while maintaining the development of chronic hepatitis treatment [1] Group 1 - The company has shifted its focus away from vaccines and viral immunotherapy [1] - Development efforts are now concentrated on chronic hepatitis treatment [1]